130 related articles for article (PubMed ID: 9722294)
1. Myelofibrosis with myeloid metaplasia in young individuals: disease characteristics, prognostic factors and identification of risk groups.
Cervantes F; Barosi G; Demory JL; Reilly J; Guarnone R; Dupriez B; Pereira A; Montserrat E
Br J Haematol; 1998 Aug; 102(3):684-90. PubMed ID: 9722294
[TBL] [Abstract][Full Text] [Related]
2. Prognostic factors and current practice in treatment of myelofibrosis with myeloid metaplasia: an update anno 2000.
Cervantes F
Pathol Biol (Paris); 2001 Mar; 49(2):148-52. PubMed ID: 11317960
[TBL] [Abstract][Full Text] [Related]
3. Identification of 'short-lived' and 'long-lived' patients at presentation of idiopathic myelofibrosis.
Cervantes F; Pereira A; Esteve J; Rafel M; Cobo F; Rozman C; Montserrat E
Br J Haematol; 1997 Jun; 97(3):635-40. PubMed ID: 9207412
[TBL] [Abstract][Full Text] [Related]
4. Myelofibrosis with myeloid metaplasia: diagnosis, prognostic factors, and staging.
Cervantes F; Barosi G
Semin Oncol; 2005 Aug; 32(4):395-402. PubMed ID: 16202685
[TBL] [Abstract][Full Text] [Related]
5. Circulating hematopoietic progenitor cells predict survival in patients with myelofibrosis with myeloid metaplasia.
Sagaster V; Jäger E; Weltermann A; Schwarzinger I; Gisslinger H; Lechner K; Geissler K; Oehler L
Haematologica; 2003 Nov; 88(11):1204-12. PubMed ID: 14607748
[TBL] [Abstract][Full Text] [Related]
6. Prognostic diversity among cytogenetic abnormalities in myelofibrosis with myeloid metaplasia.
Tefferi A; Dingli D; Li CY; Dewald GW
Cancer; 2005 Oct; 104(8):1656-60. PubMed ID: 16104040
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic and clinical relevance of the number of circulating CD34(+) cells in myelofibrosis with myeloid metaplasia.
Barosi G; Viarengo G; Pecci A; Rosti V; Piaggio G; Marchetti M; Frassoni F
Blood; 2001 Dec; 98(12):3249-55. PubMed ID: 11719361
[TBL] [Abstract][Full Text] [Related]
8. [Clinical features and prognostic factors in primary myelofibrosis patients under 45 years old].
Lu L; Xiao ZJ; Chen HS; Lin H; Han ZC
Zhonghua Xue Ye Xue Za Zhi; 2005 May; 26(5):281-4. PubMed ID: 15949290
[TBL] [Abstract][Full Text] [Related]
9. A prognostic classification of myelofibrosis with myeloid metaplasia.
Barosi G; Berzuini C; Liberato LN; Costa A; Polino G; Ascari E
Br J Haematol; 1988 Dec; 70(4):397-401. PubMed ID: 3219290
[TBL] [Abstract][Full Text] [Related]
10. Myelofibrosis with myeloid metaplasia in adult individuals 30 years old or younger: presenting features, evolution and survival.
Cervantes F; Barosi G; Hernández-Boluda JC; Marchetti M; Montserrat E
Eur J Haematol; 2001 May; 66(5):324-7. PubMed ID: 11422412
[TBL] [Abstract][Full Text] [Related]
11. Myelofibrosis with myeloid metaplasia: clinical and haematological parameters predicting survival in a series of 133 patients.
Visani G; Finelli C; Castelli U; Petti MC; Ricci P; Vianelli N; Gianni L; Zuffa E; Aloe Spiriti MA; Latagliata R
Br J Haematol; 1990 May; 75(1):4-9. PubMed ID: 2375922
[TBL] [Abstract][Full Text] [Related]
12. Myelofibrosis with myeloid metaplasia: therapeutic options in 2003.
Mesa RA
Curr Hematol Rep; 2003 May; 2(3):264-70. PubMed ID: 12901349
[TBL] [Abstract][Full Text] [Related]
13. Risks and benefits of splenectomy in myelofibrosis with myeloid metaplasia: a retrospective analysis of 26 cases.
Akpek G; McAneny D; Weintraub L
J Surg Oncol; 2001 May; 77(1):42-8. PubMed ID: 11344482
[TBL] [Abstract][Full Text] [Related]
14. Prognosis in transplant-eligible patients with agnogenic myeloid metaplasia: a simple CBC-based scoring system.
Dingli D; Schwager SM; Mesa RA; Li CY; Tefferi A
Cancer; 2006 Feb; 106(3):623-30. PubMed ID: 16369987
[TBL] [Abstract][Full Text] [Related]
15. Circulating CD34+, CD133+, and vascular endothelial growth factor receptor 2-positive endothelial progenitor cells in myelofibrosis with myeloid metaplasia.
Massa M; Rosti V; Ramajoli I; Campanelli R; Pecci A; Viarengo G; Meli V; Marchetti M; Hoffman R; Barosi G
J Clin Oncol; 2005 Aug; 23(24):5688-95. PubMed ID: 16110028
[TBL] [Abstract][Full Text] [Related]
16. Melphalan treatment in patients with myelofibrosis with myeloid metaplasia.
Petti MC; Latagliata R; Spadea T; Spadea A; Montefusco E; Aloe Spiriti MA; Avvisati G; Breccia M; Pescarmona E; Mandelli F
Br J Haematol; 2002 Mar; 116(3):576-81. PubMed ID: 11849213
[TBL] [Abstract][Full Text] [Related]
17. Myelofibrosis with myeloid metaplasia: new developments in pathogenesis and treatment.
Dingli D; Mesa RA; Tefferi A
Intern Med; 2004 Jul; 43(7):540-7. PubMed ID: 15335177
[TBL] [Abstract][Full Text] [Related]
18. Polycythemia vera in young patients: a study on the long-term risk of thrombosis, myelofibrosis and leukemia.
Passamonti F; Malabarba L; Orlandi E; Baratè C; Canevari A; Brusamolino E; Bonfichi M; Arcaini L; Caberlon S; Pascutto C; Lazzarino M
Haematologica; 2003 Jan; 88(1):13-8. PubMed ID: 12551821
[TBL] [Abstract][Full Text] [Related]
19. Treatment approaches in myelofibrosis with myeloid metaplasia: the old and the new.
Tefferi A
Semin Hematol; 2003 Jan; 40(1 Suppl 1):18-21. PubMed ID: 12682877
[TBL] [Abstract][Full Text] [Related]
20. Validation and comparison of contemporary prognostic models in primary myelofibrosis: analysis based on 334 patients from a single institution.
Tefferi A; Huang J; Schwager S; Li CY; Wu W; Pardanani A; Mesa RA
Cancer; 2007 May; 109(10):2083-8. PubMed ID: 17407134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
